| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Biochemistry |
Division of Clinical Pharmacology [C. W., R. B. K., G. R. W., A. J. J. W.], Department of Biochemistry and Center in Molecular Toxicology [F. P. G.], Vanderbilt University, Nashville, Tennessee 37232-6602, and Central Research Division, Pfizer, Inc., Connecticut 06340 [S. K.]
Many P-glycoprotein (P-gp) inhibitors studied in vitro and in vivo are also known or suspected to be substrates and/or inhibitors of cytochrome P-450 3A (CYP3A). Such overlap raises the question of whether CYP3A inhibition is an intrinsic characteristic of P-gp inhibitors, a matter of concern in the development and rational use of such agents. Thus, the purpose of the present study was to determine whether the ability to inhibit P-gp and CYP3A is, in fact, linked and whether specific P-gp inhibitors with limited ability to inhibit CYP3A can be identified. Therefore, the potency of a series of 14 P-gp inhibitors was assessed by measuring their inhibition of the transepithelial flux across Caco-2 cells of digoxin, a prototypical P-gp substrate. CYP3A inhibition was determined from the impairment of nifedipine oxidation by human liver microsomes. Determination of the apparent Ki values for CYP3A inhibition and the IC50s for P-gp and CYP3A inhibition allowed comparison of the relative inhibitory potency of the compounds on the two proteins’ function. The IC50s for P-gp inhibition ranged from 0.04 to 3.8 µM. All compounds inhibited CYP3A with apparent Ki values of between 0.3 and 76 µM and IC50s between 1.5 and 50 µM. However, no correlation was found between the extent of P-gp inhibition and CYP3A inhibition, and the ratio of the IC50 for CYP3A inhibition to the IC50 for P-gp inhibition varied from 1.1 to 125. These results demonstrate that, although many P-gp inhibitors are potent inhibitors of CYP3A, a varying degree of selectivity is present. The development and use of P-gp inhibitors with minimal or absent CYP3A inhibitory effects should decrease the impact of drug interactions on the therapeutic use of such compounds.
This article has been cited by other articles:
|
|
 |
|
  B. Kirby, E. D. Kharasch, K. T. Thummel, V. S. Narang, C. J. Hoffer, and J. D. Unadkat Simultaneous Measurement of In Vivo P-glycoprotein and Cytochrome P450 3A Activities. J. Clin. Pharmacol., November 1, 2006; 46(11): 1313 - 1319. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Rautio, J. E. Humphreys, L. O. Webster, A. Balakrishnan, J. P. Keogh, J. R. Kunta, C. J. Serabjit-Singh, and J. W. Polli IN VITRO P-GLYCOPROTEIN INHIBITION ASSAYS FOR ASSESSMENT OF CLINICAL DRUG INTERACTION POTENTIAL OF NEW DRUG CANDIDATES: A RECOMMENDATION FOR PROBE SUBSTRATES Drug Metab. Dispos., May 1, 2006; 34(5): 786 - 792. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Hong, Y. Piao, Y. Han, J. Wang, X. Zhang, Y. Du, S. Cao, T. Qiao, Z. Chen, and D. Fan Zinc ribbon domain-containing 1 (ZNRD1) mediates multidrug resistance of leukemia cells through regulation of P-glycoprotein and Bcl-2 Mol. Cancer Ther., December 1, 2005; 4(12): 1936 - 1942. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Zhao, K. L. Kunze, and C. A. Lee EVALUATION OF TIME-DEPENDENT INACTIVATION OF CYP3A IN CRYOPRESERVED HUMAN HEPATOCYTES Drug Metab. Dispos., June 1, 2005; 33(6): 853 - 861. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. K. Walker, S. Abel, P. Comby, G. J. Muirhead, A. N. R. Nedderman, and D. A. Smith SPECIES DIFFERENCES IN THE DISPOSITION OF THE CCR5 ANTAGONIST, UK-427,857, A NEW POTENTIAL TREATMENT FOR HIV Drug Metab. Dispos., April 1, 2005; 33(4): 587 - 595. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Rollot, O. Pajot, L. Chauvelot-Moachon, E. M Nazal, C. Kelaidi, and P. Blanche Acute Colchicine Intoxication During Clarithromycin Administration Ann. Pharmacother., December 1, 2004; 38(12): 2074 - 2077. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Mahadevan and A. F. List Targeting the multidrug resistance-1 transporter in AML: molecular regulation and therapeutic strategies Blood, October 1, 2004; 104(7): 1940 - 1951. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. W. Ward and L. M. Azzarano Preclinical Pharmacokinetic Properties of the P-Glycoprotein Inhibitor GF120918A (HCl salt of GF120918, 9,10-Dihydro-5-methoxy-9-oxo-N-[4-[2-(1,2,3,4-tetrahydro-6,7-dimethoxy-2-isoquinolinyl)ethyl]phenyl]-4-acridine-carboxamide) in the Mouse, Rat, Dog, and Monkey J. Pharmacol. Exp. Ther., August 1, 2004; 310(2): 703 - 709. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. S. Warrington, D. J. Greenblatt, and L. L. von Moltke The Effect of Age on P-Glycoprotein Expression and Function in the Fischer-344 Rat J. Pharmacol. Exp. Ther., May 1, 2004; 309(2): 730 - 736. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. D. Kharasch, C. Hoffer, T. G. Altuntas, and D. Whittington Quinidine as a Probe for the Role of P-Glycoprotein in the Intestinal Absorption and Clinical Effects of Fentanyl J. Clin. Pharmacol., March 1, 2004; 44(3): 224 - 233. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Harrison, A. Betts, K. Fenner, K. Beaumont, A. Edgington, S. Roffey, J. Davis, P. Comby, and P. Morgan NONLINEAR ORAL PHARMACOKINETICS OF THE {alpha}-ANTAGONIST 4-AMINO-5-(4-FLUOROPHENYL)-6,7-DIMETHOXY-2-[4-(MORPHOLINOCARBONYL)-PERHYDRO-1,4-DIAZEPIN-1-YL]QUINOLINE IN HUMANS: USE OF PRECLINICAL DATA TO RATIONALIZE CLINICAL OBSERVATIONS Drug Metab. Dispos., February 1, 2004; 32(2): 197 - 204. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Mizuno, T. Niwa, Y. Yotsumoto, and Y. Sugiyama Impact of Drug Transporter Studies on Drug Discovery and Development Pharmacol. Rev., September 1, 2003; 55(3): 425 - 461. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. P. D. Lemahieu, B. D. Maes, Y. Ghoos, P. Rutgeerts, K. Verbeke, and Y. Vanrenterghem Measurement of hepatic and intestinal CYP3A4 and PGP activity by combined po + iv [14C]erythromycin breath and urine test Am J Physiol Gastrointest Liver Physiol, August 8, 2003; 285(3): G470 - G482. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. C. Evans, D. O'Connor, B. G. Lake, R. Evers, C. Allen, and R. Hargreaves ELETRIPTAN METABOLISM BY HUMAN HEPATIC CYP450 ENZYMES AND TRANSPORT BY HUMAN P-GLYCOPROTEIN Drug Metab. Dispos., July 1, 2003; 31(7): 861 - 869. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Kumar, G. Y. Kwei, G. K. Poon, S. A. Iliff, Y. Wang, Q. Chen, R. B. Franklin, V. Didolkar, R. W. Wang, M. Yamazaki, et al. Pharmacokinetics and Interactions of a Novel Antagonist of Chemokine Receptor 5 (CCR5) with Ritonavir in Rats and Monkeys: Role of CYP3A and P-Glycoprotein J. Pharmacol. Exp. Ther., March 1, 2003; 304(3): 1161 - 1171. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. T. Huisman, J. W. Smit, H. R. Wiltshire, J. H. Beijnen, and A. H. Schinkel Assessing Safety and Efficacy of Directed P-Glycoprotein Inhibition to Improve the Pharmacokinetic Properties of Saquinavir Coadministered with Ritonavir J. Pharmacol. Exp. Ther., February 1, 2003; 304(2): 596 - 602. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Yasuda, L.-b. Lan, D. Sanglard, K. Furuya, J. D. Schuetz, and E. G. Schuetz Interaction of Cytochrome P450 3A Inhibitors with P-Glycoprotein J. Pharmacol. Exp. Ther., October 1, 2002; 303(1): 323 - 332. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Ekins, R. B. Kim, B. F. Leake, A. H. Dantzig, E. G. Schuetz, L.-B. Lan, K. Yasuda, R. L. Shepard, M. A. Winter, J. D. Schuetz, et al. Three-Dimensional Quantitative Structure-Activity Relationships of Inhibitors of P-Glycoprotein Mol. Pharmacol., May 1, 2002; 61(5): 964 - 973. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Ekins, R. B. Kim, B. F. Leake, A. H. Dantzig, E. G. Schuetz, L.-B. Lan, K. Yasuda, R. L. Shepard, M. a Winter, J. D. Schuetz, et al. Application of Three-Dimensional Quantitative Structure-Activity Relationships of P-Glycoprotein Inhibitors and Substrates Mol. Pharmacol., May 1, 2002; 61(5): 974 - 981. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. L. Cummins, W. Jacobsen, and L. Z. Benet Unmasking the Dynamic Interplay between Intestinal P-Glycoprotein and CYP3A4 J. Pharmacol. Exp. Ther., March 1, 2002; 300(3): 1036 - 1045. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. M. Baron, L. B. Goh, D. Yao, C. R. Wolf, and T. Friedberg Modulation of P450 CYP3A4-Dependent Metabolism by P-glycoprotein: Implications for P450 Phenotyping J. Pharmacol. Exp. Ther., April 13, 2001; 296(2): 351 - 358. [Abstract] [Full Text]
|
|
|
|
|
|
L. Lu, F. Leonessa, R. Clarke, and I. W. Wainer Competitive and Allosteric Interactions in Ligand Binding to P-glycoprotein as Observed on an Immobilized P-glycoprotein Liquid Chromatographic Stationary Phase Mol. Pharmacol., January 1, 2001; 59(1): 62 - 68. [Abstract] [Full Text]
|
|
|
|
|
|
S. Ibrahim, J. Peggins, A. Knapton, T. Licht, and A. Aszalos Influence of Antipsychotic, Antiemetic, and Ca2+ Channel Blocker Drugs on the Cellular Accumulation of the Anticancer Drug Daunorubicin: P-glycoprotein Modulation J. Pharmacol. Exp. Ther., December 1, 2000; 295(3): 1276 - 1283. [Abstract] [Full Text]
|
|
|
|
 |
|
 C. D. Britten, S. D. Baker, L. J. Denis, T. Johnson, R. Drengler, L. L. Siu, K. Duchin, J. Kuhn, and E. K. Rowinsky Oral Paclitaxel and Concurrent Cyclosporin A: Targeting Clinically Relevant Systemic Exposure to Paclitaxel Clin. Cancer Res., September 1, 2000; 6(9): 3459 - 3468. [Abstract] [Full Text]
|
|
|
|
|
|
C. Wandel, R. B. Kim, F. P. Guengerich, and A. J. J. Wood Mibefradil Is a P-Glycoprotein Substrate and a Potent Inhibitor of Both P-Glycoprotein and CYP3A In Vitro Drug Metab. Dispos., August 1, 2000; 28(8): 895 - 898. [Abstract] [Full Text]
|
|
|
|
|
|
E. F. Choo, B. Leake, C. Wandel, H. Imamura, A. J. J. Wood, G. R. Wilkinson, and R. B. Kim Pharmacological Inhibition of P-glycoprotein Transport Enhances the Distribution of HIV-1 Protease Inhibitors into Brain and Testes Drug Metab. Dispos., June 1, 2000; 28(6): 655 - 660. [Abstract] [Full Text]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
